Rhythm Pharmaceuticals, Inc. (BMV:RYTM)
1,866.76
-158.24 (-7.81%)
At close: Nov 18, 2025
Rhythm Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 54.3 | 89.14 | 60.08 | 127.68 | 59.25 |
Short-Term Investments | 334.65 | 231.43 | 215.77 | 205.61 | 235.61 |
Cash & Short-Term Investments | 388.95 | 320.57 | 275.85 | 333.29 | 294.86 |
Cash Growth | 21.33% | 16.21% | -17.23% | 13.04% | 70.64% |
Receivables | 26.08 | 18.51 | 14.87 | 6.22 | 1.03 |
Inventory | 25.75 | 18.74 | 8.62 | 2.92 | 0.11 |
Other Current Assets | 26.13 | 16.38 | 8.93 | 11.81 | 12.4 |
Total Current Assets | 466.92 | 374.2 | 308.27 | 354.24 | 308.39 |
Property, Plant & Equipment | 4.15 | 4.11 | 2.12 | 3.38 | 4.34 |
Other Intangible Assets | 5.32 | 6.17 | 7.03 | 7.88 | 4.66 |
Long-Term Deferred Charges | 1.66 | 6.21 | 12.59 | - | - |
Other Long-Term Assets | 2.15 | 1.58 | 2.73 | 16.98 | 12.14 |
Total Assets | 480.2 | 392.27 | 332.75 | 382.48 | 329.52 |
Accounts Payable | 13.95 | 12.33 | 4.89 | 4.8 | 5.74 |
Accrued Expenses | 79.78 | 58.31 | 42.85 | 30.48 | 29.26 |
Current Portion of Long-Term Debt | 7.3 | 1.54 | - | - | - |
Current Portion of Leases | 0.65 | - | 0.77 | 0.68 | 0.61 |
Current Unearned Revenue | 0.19 | 1.29 | 1.29 | 1.43 | 7 |
Other Current Liabilities | 4.08 | 42.05 | 5.41 | 2.42 | 0.83 |
Total Current Liabilities | 105.94 | 115.52 | 55.2 | 39.81 | 43.43 |
Long-Term Debt | 100.89 | 108.27 | 106.14 | 75.81 | - |
Long-Term Leases | 3.34 | 3.94 | 0.49 | 1.26 | 1.95 |
Other Long-Term Liabilities | - | - | 1.15 | 1.34 | - |
Total Liabilities | 210.17 | 227.72 | 162.99 | 118.22 | 45.37 |
Common Stock | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 |
Additional Paid-In Capital | 1,492 | 1,177 | 1,064 | 974.36 | 813.04 |
Retained Earnings | -1,352 | -1,155 | -894.74 | -710.06 | -528.94 |
Comprehensive Income & Other | -0.8 | -0.04 | 0.13 | -0.09 | -0 |
Total Common Equity | 139.07 | 21.73 | 169.76 | 264.26 | 284.15 |
Shareholders' Equity | 270.03 | 164.55 | 169.76 | 264.26 | 284.15 |
Total Liabilities & Equity | 480.2 | 392.27 | 332.75 | 382.48 | 329.52 |
Total Debt | 112.17 | 113.75 | 107.4 | 77.75 | 2.55 |
Net Cash (Debt) | 276.78 | 206.82 | 168.44 | 255.53 | 292.3 |
Net Cash Growth | 33.83% | 22.78% | -34.08% | -12.58% | 72.24% |
Net Cash Per Share | 4.26 | 3.39 | 2.92 | 4.90 | 5.89 |
Filing Date Shares Outstanding | 68.29 | 63.22 | 60.14 | 56.75 | 50.33 |
Total Common Shares Outstanding | 67.21 | 62.39 | 59.43 | 56.61 | 50.28 |
Working Capital | 360.97 | 258.68 | 253.07 | 314.43 | 264.96 |
Book Value Per Share | 2.07 | 0.35 | 2.86 | 4.67 | 5.65 |
Tangible Book Value | 133.75 | 15.56 | 162.73 | 256.38 | 279.49 |
Tangible Book Value Per Share | 1.99 | 0.25 | 2.74 | 4.53 | 5.56 |
Machinery | 2.69 | 2.69 | 2.7 | 2.65 | 2.37 |
Construction In Progress | 0.93 | - | - | - | - |
Leasehold Improvements | 2.73 | 2.71 | 2.71 | 2.71 | 2.71 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.